source
- Replimune's melanoma virus therapy wins FDA advisory committee vote after two rejectionsReplimune's oncolytic virus RP1, also called vusolimogene oderparepvec and Tudriqev, has been rejected twice by the FDA. Today an advisory committee voted 10 to 3 that the candidate shows enough ef…
- Rising oil prices could lift manufacturing costs of an HIV drug, Unitaid report saysRising oil prices, driven in part by geopolitical tensions, have raised concerns about the stability of medicine supply chains. Analysts note that higher energy costs can translate into increased p…